Boston Scientific Q4 2021 Earnings Report
Key Takeaways
Boston Scientific reported net sales of $3.127 billion for Q4 2021, a 15.4% increase year-over-year. GAAP net income available to common stockholders was $80 million, or $0.06 per share, while adjusted EPS reached $0.45. The company's performance was driven by growth across all reportable segments and regions.
Net sales increased by 15.4% on a reported basis, reaching $3.127 billion.
GAAP net income available to common stockholders was $0.06 per share.
Adjusted EPS reached $0.45 per share.
The company achieved net sales growth in each reportable segment.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Forward Guidance
The company estimates net sales growth for the full year 2022 to be in the range of approximately 6 to 8 percent on both a reported basis and organic basis. The company estimates EPS on a GAAP basis in a range of $0.94 to $1.04 and adjusted EPS, excluding certain charges (credits) of $1.73 to $1.79.
Positive Outlook
- Net sales growth for the full year 2022 is expected to be in the range of 6 to 8 percent.
- EPS on a GAAP basis is estimated to be in the range of $0.94 to $1.04.
- Adjusted EPS is projected to be between $1.73 and $1.79.
- Net sales growth for the first quarter of 2022 is expected to be in the range of approximately 5 to 8 percent on both a reported and organic basis.
- EPS on a GAAP basis in a range of $0.16 to $0.20 and adjusted EPS, excluding certain charges (credits) of $0.38 to $0.40 for Q1 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income